Can I Participate?

You may be eligible if you:

Are 18 years of age or older

Have a confirmed diagnosis of either type of ANCA-associated vasculitis (AAV): Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Need induction treatment with cyclophosphamide or rituximab

You will not be eligible
to participate in this study if you:   

Have eosinophilic granulomatosis with polyangiitis (EGPA)

Have had a kidney transplant

Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.  

Check Your Eligibility

Why Should I Join the AVASET Study? 

By enrolling in this study, you may receive:  

Access to a study doctor with experience managing ANCA-associated vasculitis

Reimbursement for reasonable expenses, such as travel and hotel (as allowed by the study)

The study drug at no cost

What Should I Expect?

Fill Out The Questionnaire

Submit  Online  Questionnaire  

This questionnaire will ask for your contact information and a few questions about your medical history to help determine your eligibility.  

Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.

Speak With PatientWing

PatientWing is helping to identify potential individuals who may be interested in this ANCA-associated vasculitis study. You will have a short call with PatientWing to answer additional questions about your medical history.

Speak With a Research Site

After your conversation with PatientWing, you will have the option to meet the research team who will review your medical records.

If the research team thinks you are a good fit, they will schedule a screening visit.

You will be asked to review an Informed Consent Form (ICF) before any study-specific procedures take place. The ICF explains what the study is about, what participation involves, possible risks and benefits, and your rights as a participant. You will have time to ask questions before deciding whether to sign it. Signing the ICF means you agree to take part in the screening process for the study.

The research team will provide more information during your conversations with them. No question is a bad question so please share your concerns with the team! 

Study Participation

After you've completed the screening period, the research team will notify you about your eligibility. 
If you are enrolled in the AVASET study, you should expect the following:  

You will visit the study site approximately 26 times in person. 

The study will include a 5-year treatment period where you will have an equal chance of being placed into one of three groups:

Group A: Receive the study drug and standard-of-care immunosuppressive therapy for all 5 years.

Group B: Receive the study drug for 1 year, followed by a placebo for 4 years, along with standard-of-care immunosuppressive therapy for all 5 years.

Group C: Receive a placebo and standard-of-care immunosuppressive therapy for all 5 years.

Reasonable reimbursement for travel may be provided if you qualify for the study.

Frequently Asked Questions

How is PatientWing involved in this clinical study process?

We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research! 

Will I receive compensation if I participate in the study? 

No, you will not be compensated for participating in the study. Reasonable reimbursement for travel‑related expenses may be provided if you qualify for the study. The study coordinator can provide more details.

How often do I need to visit the research site?

You will have 1 visit each month for the first 6 months. After that, you will have 1 site visit every 3 months for the remainder of the 5-year study. There are approximately 26 visits in person, which also includes a final safety follow-up visit.

Are there possible benefits of participating?

Taking part in this study may or may not help to treat your AAV. Your health could improve, stay the same, or get worse.  However, the data we get from you during this study may help doctors learn more about the study drug and whether or not it provides benefit to patients with AAV, and this may help future patients with AAV.

Is there a chance I will receive a placebo? 

Yes. Some participants may receive a placebo along with standard-of-care treatment. The study team will provide further explanation about the likelihood of receiving a placebo and the details involved.  

Have
Questions?

You can email, text, call or fill out the form with any questions. We’re here to help. 

Contact Us

Phone:

213-459-2979

Email:

studies@patientwing.com

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.